Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Why Investors Should Buy Takeda As It De-Leverages

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) suspended its plans of buying Takeda Pharmaceutical’s TachoSil on Friday. The American multinational corporation cited regulatory concerns for abandoning the deal.

Johnson & Johnson suspends plans of buying Takeda Pharmaceutical’s TachoSil

Johnson & Johnson  said on Friday it abandoned plans to buy Takeda Pharmaceutical’s surgical patch product TachoSil, citing regulatory issues.

Johnson & Johnson abandons deal for Takeda's TachoSil surgical patch

Six companies will work together to develop a plasma-derived antibody product to fight SARS-CoV-2.

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy

EU antitrust regulators have opened a full investigation into Johnson & Johnson's acquisition of Takeda Pharmaceutical's surgical patch product TachoSil, concerned that the deal could lead to reduced choice and higher prices for customers.

EU says Johnson & Johnson's deal for Takeda patch may harm competition

Emergent BioSolutions

Forget vaccines or antivirals -- antibodies from patients who have recovered could be the secret to beating COVID-19.

FDA Developing Coronavirus Treatment From Blood of Recovered Patients

BioNTech SE

Gilead Sciences

GlaxoSmithKline

Eli Lilly

Pfizer

Sanofi

The battle to defeat the coronavirus will be won. But victory won't come as quickly as anyone would like.

Big Pharma's Fight Against the Coronavirus Pandemic: Good News and Bad News

Rare Diseases Therapeutic Division Funds Phase II Rare Diseases Therapeutic Division Funds Phase II

Chembio Diagnostics and Takeda Pharmaceutical Complete Feasibility Study

AbbVie

Amgen

Bristol-Myers

Lawmakers have for years been concerned the U.S. is too reliant on foreign manufacturing of medicine.

Lawmakers pressure Big Pharma on drug supply chains amid coronavirus outbreak

Biogen

Microsoft

Slack

Zoom Video

After a COVID-19 cluster was traced to a Biogen meeting, two big Massachusetts pharmaceutical companies have asked employees to work remotely when possible.

Coronavirus Concerns Have Big Pharma Working From Home

Inovio Pharmaceuticals

Moderna

Not yet, but multiple drugmakers are working on treatments and vaccines.

Is There a Cure for the SARS-CoV-2 Coronavirus?

Plasma-derived therapies have proven effective in the treatment of severe acute viral respiratory infections.

Takeda Pharmaceutical Announces a Plasma-Derived Coronavirus Therapy

Shares of Takeda Pharmaceutical Company Ltd. TAK, -1.96% were up 6% in premarket trading on Wednesday after the Japanese drugmaker said it plans to test a hyperimmune globulin treatment for people at high risk for COVID-19.

Takeda's stock is up 6% as it details plans for a COVID-19 treatment

A huge acquisition could get this overlooked giant on investors' radar.

Is Takeda Pharmaceutical Company Stock a Buy?

The integration of Shire is progressing more quickly than the company had expected.

Takeda Pharmaceutical Raises Its Profit Outlook

Takeda Pharmaceutical Company Limited (TKPHF) Management on Q4 2019 Results - Earnings Call Transcript

Takeda Pharmaceutical Co Ltd  said it now expects an operating profit for the full year, as opposed to its earlier projection for a loss, due to sales of its main products and cost savings from its integration with Shire Plc.

Japan's Takeda forecasts surprise full-year operating profit

– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome –

LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) is banking heavily on its gene and cell therapy programs.

Investors Hope for More From Takeda Than a Healthy Dividend

This global pharmaceutical company has a healthy dividend and a bevy of new drugs set to enter the market in the coming years.

1 Attractive Pharma Stock You Probably Haven't Heard Of

General Motors

STORE Capital

Maximize your passive income by comparing yields and performance.

3  Dividend Stocks That Pay Better Than Coca-Cola

CAR-T stocks were all the rage back in 2017, catching investors' imaginations and inspiring new ways of thinking in oncology.

Takeda Takes a Big Step Into New Cancer Immunotherapy

Takeda Pharmaceutical Co. Ltd (TAK) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript

Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript

Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million

Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

News for Takeda Pharmaceutical Stock (TAK)